Alnylam trailblazer Barry Greene jumps to the helm of a struggling Sage Therapeutics. Can he deliver another comeback?
Sage Therapeutics will look to a new chief to lead the way during its comeback attempt.
Former Alnylam president Barry Greene — a well known fixture in the Boston/Cambridge hub — is taking the helm of the neuro outfit, just 6 weeks after the nearby Biogen stepped up with a multibillion-dollar bet on the smaller biotech.
After a 7-year stint as CEO, Jeff Jonas will step into a new role now as chief innovation officer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,500+ biopharma pros reading Endpoints daily — and it's free.